miRagen Therapeutics (NASDAQ:MGEN) has appointed Lee Rauch, as President, Chief Govt Officer and a Director, following the resignation of William Marshall, although he has agreed to behave as Senior Technical Advisor.

Ms. Rauch, who joined miRagen in June 2020 as its Chief Working Officer, has greater than 25 years of expertise.

The Firm plans to prioritize its assets in direction of the event of its lead compound, MRG-229 a conjugated miR-29 mimic, for Idiopathic Pulmonary Fibrosis. Later this month, miRagen is scheduled to current new information from its preclinical research of MRG-229 at the Oligonucleotide Therapeutics Society’s annual assembly.

The Firm additionally introduced that it’ll conclude its Section 2 SOLAR trial of cobomarsen in 37 sufferers with Cutaneous T-Cell Lymphoma, and report topline information by the top of this yr.

As well as, miRagen has engaged Ladenburg Thalmann to conduct a assessment of accessible strategic alternate options for the corporate.

Shares elevated ~12% AH.